Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Tularik initiates phase II studies of T-64 for treatment of solid tumors

July 19, 2000

Novel nucleoside transport inhibitor NU-3108 deemed suitable for further development

July 18, 2000

Naturally produced antiangiogenic agent identified by Eisai and Mercian

July 18, 2000

NeoRx's STR product continues to show positive phase I/II results

July 18, 2000

Phase I Endostatin trial to enroll 12 additional patients

July 14, 2000

New series of psoralen-based photochemotherapeutics claimed by Buckman Laboratories

July 13, 2000

Genta begins follow-up studies of Genasense combination therapy for prostate cancer

July 12, 2000

UT researchers patent dibenzofluorene derivatives with cytotoxic activity

July 12, 2000

Murine and humanized monoclonal antibodies against alphav integrin receptors

July 12, 2000

Biological characteristics of A-176120, a potent FPP mimetic with promise as a cancer therapeutic

July 12, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...